Financials data is unavailable for this security.
Inc stmt in HUFIncome statement in HUF
Year on year
Richter Gedeon Vegyeszeti Gyar Nyrt grew revenues 11.62% from 507.79bn to 566.78bn while net income improved 122.09% from 47.14bn to 104.68bn.
|Net profit margin||17.16%|
|Return on assets||10.31%|
|Return on equity||12.47%|
|Return on investment||11.76%|
Cash flow in HUF
Richter Gedeon Vegyeszeti Gyar Nyrt increased its cash reserves by 10.65%, or 13.69bn. The company earned 133.52bn from its operations for a Cash Flow Margin of 23.56%. In addition the company used 98.89bn on investing activities and also paid 18.29bn in financing cash flows.
|Cash flow per share||767.55|
|Price/Cash flow per share||11.49|
|Book value per share||4,403.71|
|Tangible book value per share||3,043.41|
Balance sheet in HUF
|Total debt/total equity||0.0302|
|Total debt/total capital||0.029|
Growth rates in HUF
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 257.30% and 122.14%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked the highest relative to its industry peers.
|Div yield(5 year avg)||1.71%|
|Div growth rate (5 year)||25.52%|
|Payout ratio (TTM)||42.36%|
|EPS growth(5 years)||14.13|
|EPS (TTM) vs |
TTM 1 year ago